Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM551
- Development stage
- Preclinical
- Lead developer
- Keymed Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
CM551 is a long-acting bispecific antibody developed by Keymed Biosciences for the treatment of inflammatory bowel disease (IBD). It is designed to simultaneously target and neutralize two key pro-inflammatory cytokines: TNF-like ligand 1A (TL1A) and the p19 subunit of interleukin-23 (IL-23 p19). By dual-targeting these pathways, CM551 aims to provide enhanced therapeutic efficacy for patients with Crohn's disease and ulcerative colitis compared to existing monotherapies. As of mid-2026, Keymed Biosciences has submitted an Investigational New Drug (IND) application for CM551, and the program is in the preclinical or early clinical stage of development.
- Other names
- CM551CM-551CM 551
02
Targets
IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on CM551.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM551.